Role of class II human leucocyte antigens in the progression from early to definite systemic sclerosis
Authors:
Open Access
- 16 September 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 54 (4) , 707-711
Abstract
Objective. HLAs have been extensively associated with SSc susceptibility but their role in the progression of the disease is poorly understood. In 2013 the ACR and European League Against Rheumatism (EULAR) jointly defined criteria for the classification of SSc that allow the early identification of definite SSc patients. In this study we investigated the role of HLA class II antigens in the progression from early to definite SSc. Methods. One hundred and fifty-eight subjects with early SSc according to LeRoy and Medsger criteria and no other manifestation indicative of definite SSc at referral were considered. All the patients underwent high-resolution HLA class II typing and the appraisal of definite SSc was retrospectively conducted in a prospective manner. Lifetime analysis was conducted to gauge the effect of genetic and clinical characteristics on progression of the disease. Results. The median estimated time to progression was 45 months from referral; the 5 and 10 year estimates of progression were 59.8% and 80%, respectively. ACAs were associated with a reduced risk of progression [median survival 55 vs 23 months for ACA-positive vs ACA-negative patients, P = 0.035; hazard ratio (HR) 0.67 (95% CI 0.458, 0.979)]. HLA alleles within the HLA DQ5-DR1 haplotype [HLA-DRB1*0101-HLA-DQA1*0101(4)-HLA-DQB1*0501] reduced the risk of progression of the disease [median survival 108 vs 44 months for DQ5-DR1 carriers vs DQ5-DR1 non-carriers; HR 0.388 (CI 0.211, 0.712), P = 0.001, corrected P = 0.014]. In multivariate models, the effect of genetics was found to be independent of ACA positivity or other baseline factors; additive risks were observed when the DQ5-DR1 haplotype and ACA were jointly considered. Conclusion. HLA class II alleles within the HLA DQ5-DR1 haplotype are associated with lower rates of progression from early to definite SSc.Keywords
This publication has 17 references indexed in Scilit:
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2013
- Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvementArthritis Research & Therapy, 2012
- Analysis of Class II human leucocyte antigens in Italian and Spanish systemic sclerosisRheumatology, 2011
- Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controlsAnnals of the Rheumatic Diseases, 2010
- Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty‐year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosisArthritis & Rheumatism, 2008
- Systemic sclerosis: a prototypic multisystem fibrotic disorderJournal of Clinical Investigation, 2007
- Sequence-Specific Primed PCR (PCR-SSP) Typing of HLA Class I and Class II Alleles2007
- Evidence‐based guidelines for the use of immunologic tests: Antinuclear antibody testingArthritis Care & Research, 2002
- A simple correction for multiple comparisons in interval mapping genome scansHeredity, 2001
- A New Statistical Method for Haplotype Reconstruction from Population DataThe American Journal of Human Genetics, 2001